Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
| Autor: | Melissa Pender, Sankar Swaminathan, Elena G. Gibson, Craig S. Cook, Michael Angerbauer, Emily S Spivak, Barbara E. Jones, Adam M. Spivak |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Convalescent plasma medicine.drug_class Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) SARS CoV-2 Disease Monoclonal antibody 03 medical and health sciences 0302 clinical medicine ocrelizumab humoral immunity medicine Viral rna business.industry Brief Report Multiple sclerosis COVID-19 medicine.disease AcademicSubjects/MED00290 030104 developmental biology Infectious Diseases Oncology Humoral immunity Immunology Ocrelizumab business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Open Forum Infectious Diseases |
| ISSN: | 2328-8957 |
| Popis: | We describe a case of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS-CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|